Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

ions &Corporate Communications, +49 (0)89 8565 2693, , or inthe U.S.: Laurie Doyle, Director, Investor Relations & CorporateCommunications, +1-609-524-5884, ; PharmionCorporation - Breanna Burkart/Anna Sussman, Directors, Investor Relationsand Corporate Communications, +1-720-564-9150, ; AdditionalMedia Contacts for GPC Biotech - In Europe: Brian Hudspith of Maitland, +44(0)20 7379 5151, , or in the U.S.: David Schull ofRusso Partners, LLC, +1-212-845-4271, ir@gpc-biotech.com usinvestors@gpc-biotech.com ir@pharmion.com bhudspith@maitland.co.uk david.schull@russopartnersllc.com

Web site: http://www.gpc-biotech.com/http://www.pharmion.com/

Ticker Symbol: (Frankfurt:GPC),(NASDAQ-NMS:GPCB),(NASDAQ-NMS:PHRM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy

Post Your Comments:
(Date:11/25/2009)...PRNewswire-FirstCall/ -- American Scientific Resou...leased to announce that they have opened a regiona...anghai, China. ,, ASR has been able to secure a...or the development and production of current and f...adults to be distributed and sold globally. Curre...
(Date:11/25/2009)...d, Nov. 25 From November 16-18, P...ing solutions, presented the second edition of the...he special needs of the older population. The conf...nd audiology from around the world and more than 2...with hearing loss for an opportunity to share expe...
(Date:11/25/2009)...25 AMPAC Fine Chemicals LLC (AFC),...daq: APFC ) announced today that it received the ...ard at the Annual Statewide Environmental Summit, ...nology Association (CMTA), the Industrial Environm...Council of California (CICC) held in San Diego. T...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3China Biopharmaceuticals Holdings Inc Shareholders Overwhelmingly Support Merger with NeoStem Inc a NYSE AMEX Listed Company Trading Under Symbol 5829 1China Biopharmaceuticals Holdings Inc Shareholders Overwhelmingly Support Merger with NeoStem Inc a NYSE AMEX Listed Company Trading Under Symbol 5829 2China Biopharmaceuticals Holdings Inc Shareholders Overwhelmingly Support Merger with NeoStem Inc a NYSE AMEX Listed Company Trading Under Symbol 5829 3Practice changing cancer studies presented at major cancer meeting 60320 1Practice changing cancer studies presented at major cancer meeting 60320 2Placental precursor stem cells require testosterone free environment to survive 10574 1Placental precursor stem cells require testosterone free environment to survive 10574 2
...Boston Scientific Corporation (NYSE: BSX ) today... program that show real-word survival rates for im...from clinical trials. ALTITUDE analyzes outcomes ...tient Management system. Five-year survival rate ...efibrillators (ICDs) and cardiac resynchronization...
...) (certolizumab pegol), a treatment option for adu...arthritis and moderate to severe Crohn,s disease, ...led syringe resulting from the UCB partnership wit...irectly involved with UCB and OXO(R) in the develo... -- Cimzia(R) prefilled syringe designed to make ...
Other Medicine Technology:Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 2Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 3Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 4Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 2Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 3Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 4Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 5Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 6Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 7Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 8Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 9Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 10Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 11
(Date:11/28/2009)...udy finds gene variation believed to affect circad...althDay News) -- New research suggests that an int... factor in the development of bipolar disorder in ...nation of the genetic makeup of 152 children with ...e to major mood swings, and 140 children without t...
(Date:11/27/2009)... Biotech firm Replikins Ltd...the H1N1 virus genomic data. It shows that the le...3.7 (s.d. 4.5) during the virus,s current outbreak...els this week of 2.0 (s.d. 0.1). The H1N1 infectiv... Boston (PRWEB) November 27, 2009 -...
(Date:11/27/2009)..., , NEUILLY-SUR-SEINE, France, Nov. 27 /PR...rican professional cycling team dedicated to ethic...cycling champions, announced today that it will be...Transitions Optical as a new sponsor of the team. ...turer of adaptive eyewear, offering the most advan...
(Date:11/27/2009)...aring rates to bring unprecedented medical, econom...ov. 27 (HealthDay News) -- The number of people wi...uble over the next 25 years, a new study predicts....44.1 million people with the disease, up from 23.7...f treating people with diabetes will triple, the s...
(Date:11/27/2009)... Specialist manufacturers w...oducts are saving millions of dollars by bringing ...process. Increasing numbers of pro-active medical ...erts at the concept stage of their projects, ensur...ing design processes or potentially outdated techn...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...MINNEAPOLIS, Nov. 5 ATS Medical, Inc.,(Nasdaq: A...rt cardiac,surgery products, announced today that ... Global Investment Conference at the New York Pala...tp://www.newscom.com/cgi-bin/prnh/20040202/ATSILOG...
...A well-informed consumer will be a healthy one, to...- Getting a prescription filled is such a routine ... , And that,s potentially a big mistake, according... to make themselves "medicine smart" by asking que...
...RICHMOND, Va., Nov. 5 Insmed Inc. (Nasdaq:,INSM),...euticals, announced,today that Dr. Geoffrey Allan,...esident of Insmed Therapeutic Proteins, will be pr... participate on a follow-on biologics-focused pane...
...PITTSBURGH, Nov. 5 CardiacAssist, Inc. announced ...ith the TandemHeart System,performing at least one....,In addition, the quarter ending September 30th s...ough nine months of 2008,CardiacAssist has also se...
...2009 GAAP Diluted EPS Guidance Reflects Growth of ... Third-Quarter Highlights:, -- GAAP diluted EPS...39 in third-quarter 2007 -- Diluted EPS, ex... -- Both GAAP diluted EPS, and diluted EPS exclud...
...60,000 Resources Have Been Identified and More Are... 5 The Resource Detectives,program, developed by ...A),provides a virtual volunteer opportunity for an...tectives program,energized a group of 4,000 "detec...
Other Medicine News:Health News:ATS Medical to Participate at the Rodman & Renshaw Annual Global Investment Conference 2Health News:When It Comes to Prescription Drugs, Get Smart 2Health News:When It Comes to Prescription Drugs, Get Smart 3Health News:Insmed to Present at Upcoming Healthcare Conferences 2Health News:CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results 2Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 2Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 3Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 4Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 5Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 6Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 7Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 8Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 9Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 10Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 11Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 12Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 13Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 14Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 15Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 16Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 17Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 18Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 19Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 20Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 21Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 22Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 23Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 24Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 25Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 26Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 27Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 28Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 29Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 30Health News:Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 31
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
Medicine Products: